$48.39−0.96 (−1.95%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
Conmed (CNMD) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~8.0%/yr (FY21→FY25), net margin 3.4%, and free cash flow (~$150.9M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Capex step-up ($19.8M). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲5.2%
1,374.7
FY21→FY25CAGR +8.0%/yr
Net income ($M)▼64.5%
47.1
one-off year: see footnoteCAGR −6.9%/yr
Free cash flow ($M)▼2.0%
150.9
capex stepped upCAGR +11.7%/yr
Diluted EPS▼64.5%
1.51
FY21→FY25CAGR −6.1%/yr
What the receipts whisper · what a headline number hides
Share count
+4.8%
29.4mn → 30.8mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
Capex step-up
$19.8M
▲51% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
3¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 56.2% → 54.6%. Net margin 3.4% is above the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 1,369.3 | 1,374.7 | 1,307.0 | 1,244.7 | 1,045.5 | 1,010.6 | ▲5.2% | +8.0% |
Cost of revenue | 581.0 | 624.2 | 574.0 | 568.5 | 474.2 | 442.6 | ▲8.8% | +9.0% |
Gross profit | 788.3 | 750.5 | 733.0 | 676.2 | 571.2 | 568.0 | ▲2.4% | +7.2% |
Research & development | 62.3 | 55.9 | 54.4 | 52.6 | 47.2 | 43.6 | ▲2.7% | +6.4% |
Selling, general & admin | 590.4 | 592.0 | 478.3 | 503.0 | 454.0 | 414.8 | ▲23.8% | +9.3% |
Total operating expenses | 652.7 | 647.9 | 532.7 | 555.6 | 501.2 | 458.3 | ▲21.6% | +9.0% |
Operating incomefeeds ROC rank | 135.6 | 102.6 | 200.3 | 120.6 | 70.1 | 109.7 | ▼48.8% | −1.7% |
Other income, net | −30.6 | −31.5 | −37.3 | −39.8 | −140.9 | −36.6 | — | — |
Pretax income | 105.0 | 71.1 | 163.0 | 80.8 | −70.9 | 73.1 | ▼56.4% | −0.7% |
Income tax | 31.5 | 24.1 | 30.6 | 16.4 | 9.7 | 10.6 | ▼21.4% | +22.9% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 73.4 | 47.1 | 132.4 | 64.5 | −80.6 | 62.5 | ▼64.5% | −6.9% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 2.42 | 1.51 | 4.25 | 2.04 | −2.68 | 1.94 | ▼64.5% | −6.1% |
Diluted shares (mn) | 30.13 | 30.83 | 30.91 | 30.78 | 30.50 | 29.41 | ▼0.2% | +1.2% |
| Margins | ||||||||
Gross margin38th pct in Healthcare | 57.6% | 54.6% | 56.1% | 54.3% | 54.6% | 56.2% | ▼1.5pp | −1.6pp |
Operating margin | 9.9% | 7.5% | 15.3% | 9.7% | 6.7% | 10.9% | ▼7.9pp | −3.4pp |
Net margin56th pct in Healthcare | 5.4% | 3.4% | 10.1% | 5.2% | −7.7% | 6.2% | ▼6.7pp | −2.8pp |
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was −14% vs a 19% norm for this window, likely a one-time item; see the filing.FY25 effective tax rate was 34% vs a 19% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-17 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Conmed's revenue last fiscal year?
Conmed reported revenue of $1,374.7M in fiscal 2025, up 5.2% from fiscal 2024.
What was Conmed's net income?
Conmed reported net income of $47.1M in fiscal 2025, a net margin of 3.4%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

